{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:32:25Z","timestamp":1775104345227,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04719-2","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:34:29Z","timestamp":1761978869000},"page":"5413-5420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The beneficial effects of empagliflozin-metformin combination on cardiovascular risk factors in type 2 diabetes mellitus patients"],"prefix":"10.1007","volume":"399","author":[{"given":"Maryam","family":"Aghajani Bac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Nasehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouzieh","family":"Zadhoush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"4719_CR1","doi-asserted-by":"publisher","first-page":"100852","DOI":"10.1016\/j.cpcardiol.2021.100852","volume":"47","author":"D Abushanab","year":"2022","unstructured":"Abushanab D, Al-Badriyeh D, Liew D, Ademi Z (2022) First-line treatment with empagliflozin and metformin combination versus standard care for patients with type 2 diabetes mellitus and cardiovascular disease in Qatar. A cost-effectiveness analysis. Curr Probl Cardiol 47:100852","journal-title":"Curr Probl Cardiol"},{"key":"4719_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","volume":"7","author":"SA Amiel","year":"2019","unstructured":"Amiel SA, Aschner P, Childs B, Cryer PE, de Galan BE, Frier BM, Gonder-Frederick L, Heller SR, Jones T, Khunti K (2019) Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 7:385\u201396","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4719_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.freeradbiomed.2022.03.019","volume":"184","author":"JS Bhatti","year":"2022","unstructured":"Bhatti JS, Sehrawat A, Mishra J, Sidhu IS, Navik U, Khullar N, Kumar S, Bhatti GK, Reddy PH (2022) Oxidative stress in the pathophysiology of type 2 diabetes and related complications: current therapeutics strategies and future perspectives. Free Radic Biol Med 184:114\u201334","journal-title":"Free Radic Biol Med"},{"key":"4719_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/2047487319880044","volume":"26","author":"G Buso","year":"2019","unstructured":"Buso G, Aboyans V, Mazzolai L (2019) Lower extremity artery disease in patients with type 2 diabetes. Eur J Prev Cardiol 26:114\u201324","journal-title":"Eur J Prev Cardiol"},{"key":"4719_CR5","doi-asserted-by":"publisher","first-page":"e8058","DOI":"10.1097\/MD.0000000000008058","volume":"96","author":"G Cai","year":"2017","unstructured":"Cai G, Shi G, Xue S, Lu W (2017) The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine (Baltimore) 96:e8058","journal-title":"Medicine (Baltimore)"},{"key":"4719_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4103\/ijp.IJP_669_18","volume":"53","author":"J Chacko","year":"2021","unstructured":"Chacko J, Dhandapani S, Jahagiridhar V, Swaminathan K (2021) The effects of empagliflozin on cardiometabolic risk factors in patients with type 2 diabetes: a short-term observational study. Indian J Pharmacol 53:229\u201333","journal-title":"Indian J Pharmacol"},{"key":"4719_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1161\/01.STR.32.1.133","volume":"32","author":"M Di Napoli","year":"2001","unstructured":"Di Napoli M, Papa F, Bocola V (2001) Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32:133\u201338","journal-title":"Stroke"},{"key":"4719_CR8","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.2337\/dc22-S005","volume":"45","author":"B Draznin","year":"2022","unstructured":"Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R (2022) G. American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee. 15. Management of diabetes in pregnancy: standards of medical care in diabetes-2022. Diabetes Care 45:S60\u2013S82","journal-title":"Diabetes Care"},{"key":"4719_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-020-01174-6","volume":"19","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Verma S, Fitchett D, Ofstad AP, Lauer S, Zwiener I, George J, Wanner C, Zinman B, Inzucchi SE (2020) Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. Cardiovasc Diabetol 19:1\u20139","journal-title":"Cardiovasc Diabetol"},{"key":"4719_CR10","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00125-021-05571-8","volume":"64","author":"A Green","year":"2021","unstructured":"Green A, Hede SM, Patterson CC, Wild SH, Imperatore G, Roglic G, Beran D (2021) Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia 64:2741\u201350","journal-title":"Diabetologia"},{"key":"4719_CR11","unstructured":"Kelsey JL (1996) Methods in observational epidemiology (Monographs in Epidemiology and)"},{"key":"4719_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/ph15010047","volume":"15","author":"K Kowalska","year":"2021","unstructured":"Kowalska K, Walczak J, Femlak J, M\u0142ynarska E, Franczyk B, Rysz J (2021) Empagliflozin\u2014a new chance for patients with chronic heart failure. Pharmaceuticals 15:47","journal-title":"Pharmaceuticals"},{"key":"4719_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fendo.2020.00111","volume":"11","author":"Q Lv","year":"2020","unstructured":"Lv Q, Le L, Xiang J, Jiang B, Chen S, Xiao P (2020) Liver transcriptomic reveals novel pathways of empagliflozin associated with type 2 diabetic rats. Front Endocrinol 11:111","journal-title":"Front Endocrinol"},{"key":"4719_CR14","doi-asserted-by":"crossref","unstructured":"Ozcelik S, Celik M, Vural A, Aydin B (2020) The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. Northern Clin Istanbul 7.","DOI":"10.14744\/nci.2019.22697"},{"key":"4719_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","volume":"21","author":"P Paolisso","year":"2022","unstructured":"Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, Sardu C, Mileva N, Fo\u00e0 A, Armillotta M (2022) Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol 21:77","journal-title":"Cardiovasc Diabetol"},{"key":"4719_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.12701\/yujm.2020.00563","volume":"38","author":"S Park","year":"2021","unstructured":"Park S, Park SY (2021) Can antioxidants be effective therapeutics for type 2 diabetes? Yeungnam Univ J Med 38:83\u201394","journal-title":"Yeungnam Univ J Med"},{"key":"4719_CR17","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.2337\/dcS15-3015","volume":"39","author":"RM Pollack","year":"2016","unstructured":"Pollack RM, Donath MY, LeRoith D, Leibowitz G (2016) Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 39:S244\u2013S52","journal-title":"Diabetes Care"},{"key":"4719_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4103\/2277-9175.188489","volume":"5","author":"M Pourfarzam","year":"2016","unstructured":"Pourfarzam M, Zadhoush F, Sadeghi M (2016) The difference in correlation between insulin resistance index and chronic inflammation in type 2 diabetes with and without metabolic syndrome. Adv Biomed Res 5:153","journal-title":"Adv Biomed Res"},{"key":"4719_CR19","doi-asserted-by":"publisher","first-page":"108668","DOI":"10.1016\/j.diabres.2021.108668","volume":"173","author":"X Qian","year":"2021","unstructured":"Qian X, He S, Wang J, Gong Q, An Y, Li H, Chen Y, Li G (2021) Prediction of 10-year mortality using hs-CRP in Chinese people with hyperglycemia: findings from the Da Qing diabetes prevention outcomes study. Diabetes Res Clin Pract 173:108668","journal-title":"Diabetes Res Clin Pract"},{"key":"4719_CR20","first-page":"123","volume":"9","author":"AM Saleh","year":"2022","unstructured":"Saleh AM, Zintl K, Brachmann J (2022) Combining stress speckle tracking with high-sensitivity C-reactive protein in diagnosis of coronary artery disease. J Cardiovasc Dev Dis 9:123","journal-title":"J Cardiovasc Dev Dis"},{"key":"4719_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.freeradbiomed.2013.05.050","volume":"65","author":"L Turell","year":"2013","unstructured":"Turell L, Radi R, Alvarez B (2013) The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic Biol Med 65:244\u201353","journal-title":"Free Radic Biol Med"},{"key":"4719_CR22","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.3390\/ijms25042335","volume":"25","author":"T Uzelac","year":"2024","unstructured":"Uzelac T, Smiljani\u0107 K, Taki\u0107 M, \u0160arac I, Oggiano G, Nikoli\u0107 M, Jovanovi\u0107 V (2024) The thiol group reactivity and the antioxidant property of human serum albumin are controlled by the joint action of fatty acids and glucose binding. Int J Mol Sci 25:2335","journal-title":"Int J Mol Sci"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04719-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04719-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04719-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:05:45Z","timestamp":1775099145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04719-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4719"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04719-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational cross-sectional study (Iranian Registry of Clinical Trials IR.MUI.RESEARCH.REC.1400.470) was approved by the Isfahan University of Medical Sciences Ethics Committee and was conducted by the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish declaration: not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}